Global Hemapheresis Market 2025-2035

Description

List of Tables

Hemapheresis Market Size, Share & Trends Analysis Report by Technology (Centrifugation, Membrane Separation, Selective Adsorption) by Product (Hemapheresis Devices, and Hemapheresis Disposables) by Procedure (Photopheresis, Plasmapheresis, Plateletpheresis, Leukapheresis, Erythrocytapheresis, and Others), and By Application (Hematology, Neurology, Renal Disease, and Others) Forecast Period (2025-2035)

Industry Overview

Hemapheresis market was valued at $3.8 billion in 2024 and is projected to reach $8.4 billion by 2035, growing at a CAGR of 7.6% during the forecast period (2025-2035). The market growth is driven by factors like the increasing prevalence of chronic diseases, a rising demand for blood components and plasma-derived medicines, and advancements in technology. Key restraints include the high cost of devices and procedures, limited awareness, and regulatory complexities. The market is also experiencing growth due to a focus on personalized medicine, increased government initiatives, and expanding applications in treating autoimmune and neurological disorders.

Market Dynamics

Increasing Prevalence of Chronic and Autoimmune Diseases

One of the primary drivers of the global apheresis market is the rising prevalence of chronic and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. These conditions often require therapeutic apheresis procedures, including plasmapheresis and leukapheresis, to manage symptoms and remove harmful components from the blood. Additionally, the growing incidence of hematological disorders, such as leukemia and lymphoma, has accelerated the need for advanced apheresis technologies. As the global population ages and lifestyle-related disorders rise, healthcare providers are increasingly adopting apheresis-based treatments to improve clinical outcomes and patient survival rates, thereby fueling market growth.

Technological Advancements and Innovation in Hemapheresis Devices

Rapid technological advancements in hemapheresis devices have significantly enhanced the efficiency, safety, and automation of the process. Modern apheresis systems feature improved membrane separation technologies, advanced centrifugation techniques, and real-time monitoring capabilities that ensure precision and reduce procedure time. Moreover, the adoption of single-use disposable kits has minimized the risk of cross-contamination and infection. These innovations have made hemapheresis procedures more cost-effective and accessible across hospitals and plasma collection centers. Leading manufacturers are investing heavily in R&D to develop next-generation automated systems, which are expected to further streamline plasma and cellular component collection, boosting market expansion globally.

Expansion of Plasma Collection Centers and Supportive Regulatory Frameworks

The growing demand for plasma-derived medicinal products such as immunoglobulins, albumin, and coagulation factors is driving the expansion of plasma collection centers worldwide. Governments and private organizations are establishing new donation centers and enhancing donor recruitment programs to meet the increasing plasma supply requirements. Additionally, supportive regulatory frameworks and favorable reimbursement policies in developed countries are promoting the adoption of apheresis technologies in both therapeutic and donor settings. Emerging economies in Asia-Pacific and Latin America are also witnessing rising investments in healthcare infrastructure, contributing to greater accessibility and market penetration of apheresis systems.

Market Segmentation

Based on the technology, the market is segmented into centrifugation, membrane separation, and selective adsorption.
Based on the product, the market is segmented into hemapheresis devices, and hemapheresis disposables.
Based on the procedure, the market is segmented into photopheresis, plasmapheresis, plateletpheresis, leukapheresis, erythrocytapheresis, and others.
Based on the application, the market is segmented into hematology, neurology, renal disease, and others.

Plasmapheresis led to the Largest Market Share

Among all the segments, plasmapheresis, under the procedure category, is expected to lead the global hemapheresis market with the largest share during the forecast period. Plasmapheresis is the most widely adopted apheresis procedure used for both therapeutic and donor applications, primarily due to its extensive use in treating autoimmune and neurological disorders, as well as for plasma collection in biopharmaceutical manufacturing. The growing demand for plasma-derived medicinal products such as immunoglobulins, coagulation factors, and albumin continues to drive the adoption of plasmapheresis systems across hospitals, clinics, and plasma collection centers globally. Furthermore, the expansion of plasma donation programs and the establishment of new plasma collection centers, particularly in the US, Europe, and emerging Asian economies, are further strengthening the dominance of the plasmapheresis segment in the overall market.

Hemapheresis Devices: A Key Segment in Market Growth

The hemapheresis devices segment is a key driver of market growth, supported by technological advancements and the rising need for efficient, automated blood component separation systems. These devices play a crucial role in both donor and therapeutic apheresis procedures, offering precision, speed, and enhanced safety. Modern hemapheresis devices integrate advanced features such as closed-loop control systems, improved centrifugation and membrane separation modules, and real-time data analytics that ensure accurate separation of plasma, platelets, leukocytes, or red blood cells. Automation in these systems reduces manual intervention and operational errors, thereby improving overall efficiency in clinical settings. The increasing demand for automated and portable hemapheresis machines in hospitals, blood banks, and plasma collection centers has significantly boosted sales.

In addition, the rising adoption of hemapheresis devices in the treatment of chronic diseases like leukemia, multiple sclerosis, and myasthenia gravis, along with their use in regenerative medicine and stem cell therapies, is expanding their clinical applications. Manufacturers such as Fresenius Kabi, Terumo BCT, Haemonetics, and Asahi Kasei Medical are actively investing in R&D to introduce next-generation hemapheresis platforms with enhanced user interfaces, better disposables compatibility, and higher throughput. Furthermore, increasing government initiatives to promote voluntary blood and plasma donation and the expansion of healthcare infrastructure in developing economies are expected to create lucrative opportunities for the hemapheresis devices market.

Regional Outlook

The global hemapheresis market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Market Players Outlook

The major companies operating in the global hemapheresis market include Ericsson AB, Huawei Technologies Co., Ltd., Nokia Corp., Samsung Electronics Co., Ltd., ZTE Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In May 2025, BBG Advanced Therapies launched the globe's first mobile leukapheresis center, a self-contained facility for collecting starting materials for cell and gene therapies. The center will support healthcare in over 63,000 square miles, collecting immune cells from cancer patients or community donors. The collected cells are used to create personalized therapies for patients.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global apheresis market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2024026

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Hemapheresis Market Sales Analysis - Technology | Product | Procedure | Application ($ Million)
Hemapheresis Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Hemapheresis Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Hemapheresis Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Hemapheresis Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Hemapheresis Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Hemapheresis Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Hemapheresis Market Revenue and Share by Manufacturers
Hemapheresis Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Asahi Kasei Medical
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. B. Braun Melsungen AG
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Fresenius Medical Care
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Haemonetics Corp.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Terumo BCT
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Hemapheresis Market Sales Analysis by Technology ($ Million)

5.1. Centrifugation
5.2. Membrane Separation
5.3. Selective Adsorption

6. Global Hemapheresis Market Sales Analysis by Product ($ Million)

6.1. Hemapheresis Devices
6.2. Hemapheresis Disposables

7. Global Hemapheresis Market Sales Analysis by Procedure ($ Million)

7.1. Photopheresis
7.2. Plasmapheresis
7.3. Plateletpheresis
7.4. Leukapheresis
7.5. Erythrocytapheresis
7.6. Others

8. Global Hemapheresis Market Sales Analysis by Application ($ Million)

8.1. Hematology
8.2. Neurology
8.3. Renal Disease
8.4. Others (Autoimmune Disorder)

9. Regional Analysis

9.1. North American Hemapheresis Market Sales Analysis - Technology | Product | Procedure | Application | Country ($ Million)
Macroeconomic Factors for North America
- 9.1.1. United States
- 9.1.2. Canada
9.2. European Hemapheresis Market Sales Analysis - Technology | Product | Procedure | Application | Country ($ Million)
Macroeconomic Factors for Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. France
- 9.2.6. Russia
- 9.2.7. Rest of Europe
9.3. Asia-Pacific Hemapheresis Market Sales Analysis - Technology | Product | Procedure | Application | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.3.4. India
- 9.3.5. Australia & New Zealand
- 9.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 9.3.7. Rest of Asia-Pacific
9.4. Rest of the World Hemapheresis Market Sales Analysis - Technology | Product | Procedure | Application | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 9.4.1. Latin America
- 9.4.2. Middle East and Africa

10. Company Profiles

10.1. Asahi Kasei Medical Co., Ltd.
- 10.1.1. Quick Facts
- 10.1.2. Company Overview
- 10.1.3. Product Portfolio
- 10.1.4. Business Strategies
10.2. B. Braun Melsungen AG.
- 10.2.1. Quick Facts
- 10.2.2. Company Overview
- 10.2.3. Product Portfolio
- 10.2.4. Business Strategies
10.3. Baxter International Inc.
- 10.3.1. Quick Facts
- 10.3.2. Company Overview
- 10.3.3. Product Portfolio
- 10.3.4. Business Strategies
10.4. Becton, Dickinson and Company (BD)
- 10.4.1. Quick Facts
- 10.4.2. Company Overview
- 10.4.3. Product Portfolio
- 10.4.4. Business Strategies
10.5. Cerus Corp.
- 10.5.1. Quick Facts
- 10.5.2. Company Overview
- 10.5.3. Product Portfolio
- 10.5.4. Business Strategies
10.6. Fresenius SE & Co. KGaA / Fresenius Medical Care / Fresenius Kabi
- 10.6.1. Quick Facts
- 10.6.2. Company Overview
- 10.6.3. Product Portfolio
- 10.6.4. Business Strategies
10.7. Haemonetics Corp.
- 10.7.1. Quick Facts
- 10.7.2. Company Overview
- 10.7.3. Product Portfolio
- 10.7.4. Business Strategies
10.8. HemaCare Corp.
- 10.8.1. Quick Facts
- 10.8.2. Company Overview
- 10.8.3. Product Portfolio
- 10.8.4. Business Strategies
10.9. Kaneka Corp.
- 10.9.1. Quick Facts
- 10.9.2. Company Overview
- 10.9.3. Product Portfolio
- 10.9.4. Business Strategies
10.10. Kawasumi Laboratories (SB-Kawasumi / Sumitomo Bakelite)
- 10.10.1. Quick Facts
- 10.10.2. Company Overview
- 10.10.3. Product Portfolio
- 10.10.4. Business Strategies
10.11. Macopharma SA
- 10.11.1. Quick Facts
- 10.11.2. Company Overview
- 10.11.3. Product Portfolio
- 10.11.4. Business Strategies
10.12. Medica S.p.A. (Medica)
- 10.12.1. Quick Facts
- 10.12.2. Company Overview
- 10.12.3. Product Portfolio
- 10.12.4. Business Strategies
10.13. Miltenyi Biotec
- 10.13.1. Quick Facts
- 10.13.2. Company Overview
- 10.13.3. Product Portfolio
- 10.13.4. Business Strategies
10.14. Nikkiso Co., Ltd. (NIKKISO)
- 10.14.1. Quick Facts
- 10.14.2. Company Overview
- 10.14.3. Product Portfolio
- 10.14.4. Business Strategies
10.15. Nipro Corp.
- 10.15.1. Quick Facts
- 10.15.2. Company Overview
- 10.15.3. Product Portfolio
- 10.15.4. Business Strategies
10.16. NxStage
- 10.16.1. Quick Facts
- 10.16.2. Company Overview
- 10.16.3. Product Portfolio
- 10.16.4. Business Strategies
10.17. Otsuka Holdings / JIMRO
- 10.17.1. Quick Facts
- 10.17.2. Company Overview
- 10.17.3. Product Portfolio
- 10.17.4. Business Strategies
10.18. Therakos, Inc.
- 10.18.1. Quick Facts
- 10.18.2. Company Overview
- 10.18.3. Product Portfolio
- 10.18.4. Business Strategies
10.19. Mallinckrodt plc
- 10.19.1. Quick Facts
- 10.19.2. Company Overview
- 10.19.3. Product Portfolio
- 10.19.4. Business Strategies
10.20. Ceramics
- 10.20.1. Quick Facts
- 10.20.2. Company Overview
- 10.20.3. Product Portfolio
- 10.20.4. Business Strategies